Cure, care, and commitment: What can we look forward to?

Diabetes Care

Volumn 31, Issue 5, 2008, Pages 1051-1059

  Rizza, Robert ^a,d   Eddy, David ^b   Kahn, Richard ^c  

^a MAYO CLINIC   (United States)

^b Archimedes Inc   (United States)

^c AMERICAN DIABETES ASSOCIATION   (United States)

^d Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE;

ARTICLE; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; COST BENEFIT ANALYSIS; DIABETES MELLITUS; DIAGNOSIS RELATED GROUP; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HEALTH CARE SYSTEM; HOSPITAL CHARGE; HUMAN; INSULIN RESISTANCE; REIMBURSEMENT; RISK ASSESSMENT; RISK FACTOR; SIMULATION; THEORETICAL MODEL; ATTITUDE TO HEALTH; FORECASTING;

ATTITUDE TO HEALTH; DIABETES MELLITUS; FORECASTING; HUMANS;

EID: 48649108635     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc08-9019     Document Type: Article

References (21)

1. Cowie CC, Rust KF, Byrd-Holt DD, Eber- hardt MS, Flegal KM, Engelgau MM, Say- dah SH, Williams DE, Geiss LS, Gregg EW: Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002. Diabetes Care 29:1263-1268, 2006
2. American Diabetes Association: Economic costs of diabetes in the U.S. in 2007. Diabetes Care 31:596-615, 2008
3. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B: Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29:1963-1972, 2006
4. American Diabetes Association: Standards of care in diabetes-2008. Diabetes Care 31 (Suppl. 1):12-54, 2008
5. Resnick HE, Foster GL, Bardslet J, Ratner RE: Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002. Diabetes Care 29:531-537, 2006
6. Schlessinger L, Eddy DM: Archimedes: a new model for simulating health care systems-the mathematical formulation. J Biomed Inform 35:37-40, 2002
7. Eddy DM, Schlessinger L: Archimedes: a trial validated model of diabetes. Diabetes Care 26:3093-3101, 2003
8. Eddy DM, Schlessinger L: Validation of the Archimedes diabetes model. Diabetes Care 26:3102-3110, 2003
9. Eddy DM, Schlessinger L, Kahn R: Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med 143:251-264, 2005
10. Schlessinger L, Eddy DM: Equations for the Archimedes model [Technical Report online]. Available from http://archimedes model.com. Accessed 1 February2008
11. NHANES 4 [article online]. Available from http://www.cdc.gov/nchs/nhanes. htm. Accessed 1 February 2008
12. BrownJB, Pedula KL, Bakst AW: The progressive cost of complications in type 2 diabetes mellitus. Arch Intern Med 159: 1873-1880, 1999
13. McGlynn EA, Asch SM, Adams J, KeeseyJ, Hicks J, DeCristofaro A, Kerr EA: The quality of health care delivered to adults in the United States. N Engl J Med 348: 2635-2645, 2003
14. Saaddine JB, Cadwell B, Gregg EW, En- gelgau MM, Vinicor F, Imperatore G, Narayan KM: Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002. Ann Intern Med 144:465-474, 2006
15. Vijan S, Hofer TP, Hayward RA: Estimated benefits of glycemic control in microvascular complications in type 2 diabetes. Ann Intern Med 127:788-795, 1997
16. Brandle M, Davidson MB, Schriger DL, Lorber B, Herman WH: Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes. Diabetes Care 26:1796-1801, 2003
17. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383-393, 2003
18. Rosen AB, Hamel MB, Weinstein MC, Cutler DM, Fendrick AM, Vijan S: Cost- effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med 143:89-99, 2005
19. Wald NJ, Law MR: A strategy to reduce cardiovascular disease by more than 80%. BMJ 326:1419, 2003
20. Gaziano TA, Opie LH, Weinstein MC: Cardiovascular disease prevention with a multi-drug regimen in the developing world: a cost-effectiveness analysis. Lancet 368:679-686, 2006
21. Eckel RH, Kahn RA, Robertson RM, Rizza RA: Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. Diabetes Care 29:1697-1699, 2006